SCHEMBL25110930

SCHEMBL25110930

CC(C)CCCOCCOCCOCC(=O)NCCCC(C)S

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GLP1R P43220 5/20 0.35
HPGD P15428 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
MAPT P10636 2/20 0.32
HSD17B10 Q99714 2/20 0.32
EPHX2 P34913 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25110640 1.00 TSHR (0.36) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL25706805 0.97 HPGD (0.36) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL22526077 0.93 TSHR (0.40) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL24673317 0.93 TSHR (0.40) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL24672702 0.93 TSHR (0.40) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL23945414 0.89 HPGD (0.40) TSHRRECQLKMT2AMEN1HPGD
SCHEMBL22527257 0.87 TSHR (0.37) TSHRRECQLKMT2AMEN1GLP1R
SCHEMBL24514221 0.85 TSHR (0.50) TSHRRECQLGLP1RALDH1A1MAPT
SCHEMBL25123197 0.85 TSHR (0.47) TSHRRECQLGLP1RALDH1A1MAPT
SCHEMBL25122630 0.85 TSHR (0.47) TSHRRECQLGLP1RALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 TSHR 3796/4885RECQL 793/4885KMT2A 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.